Near-Infrared Imaging for Perfusion Assessment of Traumatic Soft Tissue and Skeletal Injuries (IMPACT)

March 18, 2024 updated by: Joost R. van der Vorst, MD, PhD, Leiden University Medical Center

To date, intraoperative assessment of tissue and bone viability is predominantly subjective, depending on the clinical view of the surgeon, resulting in a variation in the thoroughness of debridement. Inadequate initial resection leads to multiple debridement interventions, leading to prolonged hospitalization or readmission with consequently high direct medical costs.

Near-Infrared Fluorescence (NIRF) imaging with Indocyanine Green (ICG) could potentially be a relevant contribution to adequately treating soft tissue and skeletal injuries by creating an improved distinction between viable and non-viable tissue, based on perfusion indices.

This study evaluates whether intraoperative perfusion assessment with ICG fluorescence imaging is a feasible and quantifiable technique for treating traumatic injuries.

Study Overview

Detailed Description

Rationale: In 2020 71.623 Dutch patients were acutely admitted to hospitals due to sustained traumatic injuries. 7% of the injuries related to open wounds and 44% to fractures. The majority of traumatic musculoskeletal injuries needs to be diagnosed and treated as soon as possible to lower the risk of infections and to minimize adverse outcome, such as necrosis and/or osteomyelitis. To date, intraoperative assessment of tissue and bone viability is predominantly subjective, resulting in a variation in thoroughness of debridement. If not all necrotic tissue is removed, suboptimal healing occurs, which serves as a potential food source for bacteria. In addition, inadequate initial resection leads to multiple debridement interventions, leading to prolonged hospitalization or readmission with consequently high direct medical costs. Since tissue necrosis is an ongoing process, radical resection of avital tissue during the initial procedure is not always possible. The surgeon's visual estimation is not optimal to predict the final amount of debridement. After maximal debridement, antibiotic treatment and coverage of open wounds, the incidence of infection can rise to 27%. Compromised perfusion is at the centre of this problem. An adequate blood supply is crucial for tissue viability and infection clearance.

Near-Infrared Fluorescence (NIRF) imaging with Indocyanine Green (ICG) has already shown its potential in effective real-time assessment of intra-operative tissue perfusion and the early prediction of future necrosis in multiple studies. This technique could potentially be a relevant contribution in adequately treating soft tissue and skeletal injuries by creating an improved distinction between viable and non-viable tissue, based on perfusion indices. However to date, the feasibility to quantify this technique in posttraumatic tissue has not been successfully evaluated.

Objective: The primary objective of this study is to evaluate the feasibility of Near-infrared Fluorescence (NIRF) imaging with Indocyanine green (ICG) to assess and quantify tissue perfusion in post-traumatic soft tissue and/or skeletal injury.

Study design: The study is a prospective observational multicentre pilot study. All included patients will undergo a perfusion assessment using ICG NIR fluorescence imaging. Perfusion assessment will not affect treatment of patients.

Study population: Patients aged 18 years or older with traumatic soft tissue and/or skeletal injury. Injuries included in the study are: open deglovement; crush injuries of extremities; open fractures, non-unions of clavicula, tibia, humerus, rib and/or ulna fractures and fracture related infections.

Intervention: Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.

Main study parameters/endpoints: The primary outcome of this study is a time-intensity curve with quantified perfusion parameters in traumatic soft tissue and/or skeletal injuries. Perfusion parameters included in the analyses are time till maximum intensity (Tmax), maximum intensity (Imax) the ingress rate, the normalized slope, the absolute slope and the area under the curve at 30, 60 and 120 seconds.

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Zuid-Holland
      • Leiden, Zuid-Holland, Netherlands, 2333ZA
        • Recruiting
        • Leiden University Medical Center
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Stefan Koning, MD
      • Rotterdam, Zuid-Holland, Netherlands, 3000 CA
        • Recruiting
        • Erasmus University Medical Center
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

In order to be eligible to participate in this study, a subject must meet all the following criteria:

  • Age ≥ 18 years
  • Diagnosed with one or more of the following injuries:

    • Crush injury
    • Open deglovement
    • Open fracture(s) (Gustilo 3, -A, -B & -C)
    • Non-union tibia/clavicula/ulna/humerus/rib
    • Fracture related infection
  • Indication for surgical intervention

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  • Hemodynamically unstable due to severe blood loss
  • Allergic or hypersensitive to iodine/crustaceans/shellfish
  • Diagnosed with endocrine thyroid disorders (hyperthyroidism)
  • Pregnancy
  • Diagnosed with impaired renal function eGFR <30 L/min/1.73m2
  • Diagnosed with severely disturbed hepatic enzymes/liver failure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Traumatic injuries

Acute patients treated surgically for:

  • Open deglovement (n=20)
  • Crush injury (n=20)
  • Open fractures (n=20)

The setting is defined acute when there is less than 24 hours between sustaining the injury and surgery.

Elective patients treated surgically for:

  • Fracture related infection (FRI) (n=10)
  • Non-union of fractures (n=50) Subdivided into 5 groups of 10.

    • Elective osteosynthesis of non-union clavicula fracture N=10

      • Primarily operated on N=5
      • Primarily treated conservatively N=5
    • Elective osteosynthesis of non-union tibia. N=10
    • Elective osteosynthesis of non-union ulna. N=10

      • Primarily operated on N=5
      • Primarily treated conservatively N=5
    • Elective osteosynthesis of non-union humerus. N=10
    • Elective osteosynthesis of non-union of the rib. N=10
Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time-intensity curves
Time Frame: 1 day
The main endpoint of this study is an adequate time-intensity curve extracted from selected regions of interest. Adequate curves are defined as reproducible curves with accurate representation of the perfusion status. An adequate curve is characterized by a recognisable in- and outflow pattern representing the bloodflow in the tissue. Distinguishing between adequate, questionable and inadequate perfusion can only be done after comparing the measurement results.
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum intensity (Imax)
Time Frame: 1 day

As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:

• Maximum intensity (Imax) in arbitrary units (a.u.)

1 day
Time till maximum intensity (Tmax)
Time Frame: 1 day

As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:

• Time till maximum intensity (Tmax), in seconds.

1 day
The ingress rate and absolute slope
Time Frame: 1 day

As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:

  • The ingress rate
  • The absolute slope Both in arbitrary units per second (a.u./s)
1 day
The normalized slope
Time Frame: 1 day

As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:

• The normalized slope in percentages per second (%/s)

1 day
The area's under the curve at 30, 60 and 120 seconds
Time Frame: 1 day

As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:

• Area under the curve at 30, 60 and 120 seconds in percentages (%)

1 day
Incidence of necrotic tissue
Time Frame: 90 days of necrotic

Perfusion parameters will be evaluated for their correlation with the occurrence of necrotic tissue after initial debridement.

This will be calculated as the percentage of people with inadequate perfusion parameters that develop necrotic tissue compared to people with adequate perfused tissue.

90 days of necrotic
The amount of additional debridement procedures
Time Frame: 90 days

The number of additional debridement procedures when comparing the group with inadequate perfused tissue to the group with adequate perfused tissue.

In numbers and percentages.

90 days
The infection incidence
Time Frame: 90 days

Perfusion parameters will be evaluated for their correlation with the occurrence of wound infection within 90 days after procedure. Infection defined as a red, swollen and painful area that is warm and tender to touch, possibly in combination with fever/chills, purulent effusion, positive cultures or increased infection parameters. The group with adequate perfused tissue will be compared to the group with inadequate perfusion.

This will be in numbers and percentages.

90 days
The incidence of a fracture related infection
Time Frame: 90 days
Incidence of a fracture related infection will be compared between the groups with adequate and inadequate perfusion in numbers and percentages.
90 days
Lentgh of hospital stay
Time Frame: 90 days
The length of hospital stay will be measured in days and compared between groups with adequate and inadequate perfusion.
90 days
Amount of readmission
Time Frame: 90 days
The number of readmissions within 90 days associated with complications of primary problem (infection, necrosis, death) will be compared between the groups with inadequate and adequate tissue perfusion in numbers and percentages.
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Director: Stefan Koning, MD, Leiden University Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 13, 2023

Primary Completion (Estimated)

September 10, 2025

Study Completion (Estimated)

November 10, 2025

Study Registration Dates

First Submitted

August 29, 2023

First Submitted That Met QC Criteria

September 5, 2023

First Posted (Actual)

September 13, 2023

Study Record Updates

Last Update Posted (Actual)

March 20, 2024

Last Update Submitted That Met QC Criteria

March 18, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NL84014.058.23

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Perfusion

Clinical Trials on Near-infrared fluorescence imaging of perfusion

Subscribe